Guardant Health, Inc. (GH)

Guardant Health's stock has seen significant movement in the past six months. As of January 2, 2026, the share price was $101.75, a substantial increase from $33.76 on January 3, 2025. The 52-week high is $113.91, and the 52-week low is $34.88. Recent positive events include strong 2025 preliminary revenue growth, a rapid increase in Shield colorectal cancer screening tests, analyst optimism, ADLT rate inclusion, and Medicare Advantage and commercial coverage. Despite revenue growth, the company remained cash-flow negative but aims to be free cash flow breakeven in Q4 2027. Insider selling has been noted.

There is no explicit indication of significant demand seasonality for Guardant Health's products and services. Minor fluctuations might occur due to the number of working days in a quarter, but there isn't a strong, recurring seasonal pattern of demand. Demand is likely driven more by ongoing cancer diagnoses, treatment protocols, and screening initiatives rather than specific seasonal trends. The company is actively investing in scaling its commercial organization to capture growing demand.

Guardant Health, Inc. is a precision oncology company focused on transforming cancer care through liquid biopsy technology. Founded in 2011 and based in Palo Alto, California, it operates in the biotechnology and diagnostics industries, focusing on advanced molecular diagnostics. The company aims to improve patient outcomes by providing clinicians with genomic insights across all stages of cancer care. Its major products include Guardant360 (LDT and CDx), Guardant360 TissueNext, Guardant Reveal, Shield, GuardantOMNI and GuardantINFINITY, Smart Liquid Biopsy Platform, and Development Services.

Guardant Health provides blood and tissue tests and data sets in the United States and internationally. The company has expanded its operations globally, establishing partnerships with cancer centers in Europe and Asia. In Japan, Guardant Health has received regulatory approval for its Guardant360 CDx test and the Japanese government has approved national reimbursement for the test. They are also planning to expand the self-based Shield in select markets outside the United States.

Guardant Health maintains a strong reputation as a leader in precision oncology and liquid biopsy technology. The company is recognized for its scientific foundation, proprietary technology, and clinical validation. Key events contributing to its reputation include the FDA approval of Shield, product expansions and clinical partnerships, strong revenue growth and oncology volume acceleration, and analyst endorsements. While the company faces financial challenges, its innovative potential and market leadership underpin its brand reputation.

Guardant Health has a diverse ownership structure, with a significant portion held by institutional investors. Approximately 83.41% to 92.60% of the company's stock is owned by institutional shareholders. Insiders hold between 2.24% and 33.63% of the stock, while public companies and individual investors hold around 14.35% to 15.84%. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. Significant individual or insider owners include Softbank Vision Fund Aiv M1 LP, Amirali Talasaz, and Helmy Eltoukhy.